On March 21, 2019, the group of workers on the Penn Memory Center in Philadelphia was once scrambling to be told extra about an early-morning announcement: Two pharmaceutical firms, Biogen and Eisai, would discontinue their scientific trial of a drug supposed to sluggish the development of early Alzheimer’s illness. A